Invivyd Q1 net loss $43.5M ($0.38/sh); launches PEMGARDA, guides 2024 rev $150-200M

Invivyd, Inc.

2024-Q1 EPS reported -$0.38

Launched PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised; received CMS HCPCS Q and M codes.
Cash $189.4M at Q1 end; expects ≥$75M year-end cash on $150-200M net product revenue.
Net loss $43.5M vs $35.3M YoY; R&D $31.2M, SG&A $14.9M.
Plans to submit EUA for pemivibart as COVID-19 treatment in immunocompromised via rapid immunobridging.
Advancing VYD2311 mAb candidate optimized against BA.2.86/JN.1 lineages.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Invivyd, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in, EPS Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Net income: Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in
EPS: Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 9, 2024, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024, and recent business highlights.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-135260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.